Quantum stocks soar as U.S. reportedly plans $2 billion ‘award’ and taking equity stakes

The U.S. government is reportedly awarding $2 billion in grants to nine quantum-computing firms, including $1 billion for IBM, $375 million for GlobalFoundries, and $100 million each for D-Wave Quantum, Rigetti Computing and Infleqtion. Diraq is set to receive $38 million. Shares reacted sharply in premarket trading, with IBM up 6.3%, D-Wave up 16.6%, Rigetti up about 15%, and Infleqtion up more than 26%.

Analysis

This looks less like a pure “quantum re-rating” and more like a credibility event that de-risks the sector’s funding overhang. Government equity-linked capital can compress the cost of capital for the better-capitalized incumbents while widening the gap versus subscale names that still need repeated dilutive raises to survive into commercial relevance. In that sense, IBM is the cleaner beneficiary: not because quantum moves the near-term P&L, but because it strengthens the narrative around its research moat and gives management more optionality to bundle quantum with high-margin enterprise and mainframe/workload displacement services.

The second-order winner may be the infrastructure layer, especially foundry, packaging, cryogenics, and specialized components. If the program is real and not just a one-off headline, it increases procurement confidence for long-lead suppliers and can pull forward orders for experimental systems, test equipment, and control electronics. That said, the public-market reaction in the pure plays is likely to overshoot fundamentals: these names remain years away from meaningful revenue, so the market is pricing policy validation rather than cash flow improvement.

The main risk is a fast fade once investors realize the grant checks do not equal de-risked commercialization. Quantum is still an execution story with high technical failure rates, and any slip in milestones, dilution, or change in administration posture could hit the smaller names hard over the next 1-3 months. IBM’s move is more durable over 6-12 months because it can use the announcement to reinforce a broader AI/advanced computing premium, but even there the near-term upside should be capped unless follow-on enterprise demand shows up.

Consensus may be underestimating how much this helps incumbents relative to startups. The market is treating the grants as a bullish umbrella for the whole space, but capital inflows often consolidate share around the few firms that can convert government validation into actual customer trust, hiring leverage, and financing access. That argues for relative-value exposure rather than outright beta chasing.

Key Decisions for Investors

• Long IBM vs. QBTS as a 1-3 month relative-value pair: IBM has a plausible path to retain the premium from policy validation, while QBTS likely gives back part of the premarket move once traders refocus on commercialization risk.
• Fade the open in RGTI/RGTIW with tight risk controls over 3-10 trading days: the move is driven by headline sentiment, but the warrants and small-cap structure leave them vulnerable to a liquidity unwind if volume normalizes.
• Use any post-open pullback to add IBM on a 3-6 month horizon, targeting a lower-volatility compounder trade rather than a quantum-specific thesis; stop if the stock fully retraces the event premium within two weeks.
• Overweight GFS on a 2-4 month view if the market starts extrapolating supplier demand: this is the cleaner way to express a pick-and-shovel trade, with better balance sheet quality and less binary technology risk than the pure plays.
• Avoid outright long-dated calls in the smaller quantum names unless using defined-risk structures; implied volatility likely collapses after the initial headline, so the better expression is call spreads or pair trades, not naked upside.